Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL19063434 | 0.90 | TDP1 (0.60) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL431430 | 0.90 | TDP1 (0.60) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL4778534 | 0.88 | TDP1 (0.56) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL28738366 | 0.88 | TDP1 (0.56) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL476629 | 0.85 | NAPRT (0.53) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL873759 | 0.85 | TDP1 (0.53) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL29089921 | 0.82 | NAPRT (0.50) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL1819960 | 0.80 | TDP1 (0.47) | TDP1NAPRTTSHRALDH1A1HSD17B10 | |
| Pyridine SCHEMBL31396433 | 0.79 | — | — | |
| Pyridine SCHEMBL407438 | 0.78 | NAPRT (0.60) | TDP1NAPRTTSHRALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107586288-B | A kind of purification process of Vonoprazan fumarate | 上海博志研新药物技术有限公司 | 2019-11-19 | — | — | CN | disclosed |
| CN-106518845-B | Kynurenin -3- monooxygenase inhibitor, pharmaceutical composition and its application method | CHDI基金会股份有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-108558744-A | A kind of preparation method of 2- methoxyl groups -4- trifluoromethyl -3- pyridine sulfonyl chlorides | 常州大学 | 2018-09-21 | — | — | CN | disclosed |
| CN-107586288-A | A kind of purification process of Vonoprazan fumarate | 上海博志研新药物技术有限公司 | 2018-01-16 | — | — | CN | disclosed |
| CN-106518845-A | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI基金会股份有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-103957913-B | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-11-30 | — | — | CN | disclosed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20030114437-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-06-19 | — | — | US | disclosed |
| EP-1278502-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114437-A1 | Protease inhibitors | CTSS, CTSE, CTSF | TDP1 2475/4885NAPRT 4210/4885TSHR 4050/4885 |
| US-20040229863-A1 | Protease inhibitors | CTSS, CTSE, CTSF | TDP1 2475/4885NAPRT 4210/4885TSHR 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.